Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Be­fore I owned a record la­bel, I used to write a syn­di­cat­ed al­bum re­view col­umn. One of the se­ries we ran was on the ‘gold­en streaks’ – the 3 al­bum runs that have tend­ed to de­fine the peak of the ca­reers of most of the ‘clas­sic artists’, from Ste­vie Won­der to Sina­tra to Led Zep­pelin. It is pos­si­ble that we have just wit­nessed our own in­dus­try’s punk pe­ri­od – old­er artists still sell­ing well, bring­ing in the crowds, but the pow­er now be­ing in the hands of small­er, self-made artists, who may nev­er feel com­pelled to ‘sell out’.

The Phar­ma­ceu­ti­cal In­no­va­tion In­dex mea­sures, scores and cel­e­brates a com­pa­ny’s abil­i­ty to de­liv­er in­no­va­tion to pa­tients, by ob­jec­tive­ly eval­u­at­ing per­for­mance based on a rolling five year pe­ri­od (2013-2018), and op­er­ates on the sim­ple premise: if you gave the same mol­e­cule to two dif­fer­ent com­pa­nies in ear­ly phase, which would make the best of it? This year pro­vides per­haps the strongest in­di­ca­tion yet of how un­even­ly dis­trib­uted that com­pe­ten­cy (launch­ing mean­ing­ful med­i­cines) is…

Gilead has risen con­sis­tent­ly, by one place per year since 2016, to the top of the ta­ble, with an out­stand­ing an­tivi­ral per­for­mance – in 2018, Gilead de­rived 60% of its rev­enues from new drugs, more than twice any oth­er com­pa­ny, and 6 times more than the av­er­age across the top 30. It should al­so be not­ed that Gilead are the on­ly com­pa­ny con­sis­tent­ly de­liv­er­ing new drugs that hit what we’d tra­di­tion­al­ly call ‘block­buster’ sta­tus with­in 2-3 years of launch.

There is no gam­ing the Phar­ma­ceu­ti­cal In­no­va­tion In­dex – suc­cess is achieved by dis­cov­er­ing and de­vel­op­ing mean­ing­ful­ly great med­i­cines and get­ting those med­i­cines to mar­ket, and to pa­tients. What Gilead has achieved is re­mark­able – they have re­de­fined suc­cess for this in­dus­try – launch­ing tru­ly mean­ing­ful med­i­cines that swing for the bleach­ers rather than bunt, em­brac­ing nov­el­ty and orig­i­nal­i­ty over in­cre­men­tal­ism. How­ev­er, the In­dex al­so shows that suc­cess­ful in­no­va­tion is not even­ly dis­trib­uted – more than half of the top 30 com­pa­nies did not achieve an ap­proval in 2018. 2019 al­so marks the first time in the nine years of PII that J&J have not been in the Top 10, the in­verse of Gilead’s jour­ney over that same time. (To be bal­anced, Gilead haven’t yet proven that they can take an­tivi­ral skills in­to an­oth­er ther­a­peu­tic area.)

In a year that showed a record num­ber of new drug ap­provals at the FDA, it is no­table that over half were for rare dis­eases, and 39 of the 59 FDA ap­provals went to small- to mid-sized biotech (com­pa­nies out­side of the top 30), sug­gest­ing that there are sig­nif­i­cant in­no­va­tion and pro­duc­tiv­i­ty chal­lenges for large phar­ma in the com­ing years. It al­so sug­gests that, for those 39 com­pa­nies and their 39 ap­provals, the most im­por­tant next step is to prove they can suc­cess­ful­ly com­mer­cialise. As Scott Got­tlieb has hint­ed, it is not the reg­u­la­tors who are hold­ing up the in­dus­try’s in­no­va­tion – maybe it’s the ma­jor la­bels who haven’t yet learned to cope with the in­dies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER